• Mutation; HGNC; HGNC:6342; KIT; Simple; p.Met541Leu (c.1621A>C); ClinVar=VCV000041599; Zygosity=Heterozygous (PubMed=27822414).
  
• Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Ile391Met (c.1173A>G); ClinVar=VCV000135038; Zygosity=Heterozygous (PubMed=27822414).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Heterozygous (PubMed=27822414).
  

DOI=10.14288/1.0319145
Alyssa Dawson;
Targeted therapy in low-grade serous ovarian carcinoma: characterization of MEK inhibitor response in novel patient-derived cell lines.
Thesis PhD (2016); University of British Columbia; Vancouver; Canada

PubMed=27822414; PMCID=PMC5088288
Marta Llaurado Fernandez, Gabriel E. DiMattia, Alyssa Dawson, Sylvia Bamford, Shawn Anderson, Bryan T. Hennessy, Michael S. Anglesio, Trevor G. Shepherd, Clara M. Salamanca, Josh Hoenisch, Anna Tinker ...Show all 13 authors... , David G. Huntsman, Mark S. Carey; Show fewer authors
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.
Am. J. Cancer Res. 6:2235-2251(2016)

PubMed=28545687; DOI=10.1016/j.ygyno.2017.05.019
Ismail Mert, Jasdeep Chhina, Ghassan Allo, Jing Dai, Shelly Seward, Mark S. Carey, Marta Llaurado, Shailendra Giri, Ramandeep Rattan, Adnan R. Munkarah;
Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Gynecol. Oncol. 146:319-326(2017)